AXL is frequently overexpressed in solid tumors, such as pancreatic and breast cancers, and is associated with worse prognosis and resistance to antitumor treatments (radiotherapy, chemotherapy, and targeted therapy).19, 21, 22, 23. This evidence concerns the gene AXL and breast cancer.